Literature DB >> 28224373

Drug-Induced Liver Injury in the Setting of Glycogenic Hepatopathy.

Valmiki Maharaj1, Matthew Fitz2, Xianzdong Ding3.   

Abstract

Glycogenic hepatopathy (GH) is an underdiagnosed complication of uncontrolled type 1 diabetes mellitus (T1DM). It appears as an acute relapsing hepatitis with reversible transaminase elevations secondary to excessive hepatic glycogen accumulation. Patients are often asymptomatic but can present with abdominal pain, nausea and vomiting. Physical examination shows hepatomegaly without splenomegaly. GH is diagnosed by biopsy as it is clinically indistinguishable from non-alcoholic fatty liver disease (NAFLD), a more common cause of hepatic dysfunction in diabetics. Here we describe a case of GH in a patient with uncontrolled type 1 diabetes whose clinical course was complicated by drug-induced liver injury. The patient initially presented with diabetic ketoacidosis and had a mild transaminitis, thought to be due to NAFLD. She developed profound transaminase elevations while receiving treatment with newer antipsychotic medications for her bipolar disorder. Liver biopsy showed evidence of resolving glycogenic hepatopathy with signs of drug-induced liver injury. This case report reviews the pathology and pathogenesis of GH and reminds the clinician to keep GH within the differential diagnosis for severe transaminitis in a patient with type 1 diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28224373      PMCID: PMC5442014          DOI: 10.1007/s11606-017-3996-z

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  11 in total

1.  Glycogenic hepatopathy: a rare disease that can appear and resolve rapidly in parallel with glycemic control.

Authors:  Tarek Saadi
Journal:  Isr Med Assoc J       Date:  2012-04       Impact factor: 0.892

2.  Complete reversal of glycogen hepatopathy with pancreas transplantation: two cases.

Authors:  Jonathan A Fridell; Romil Saxena; Naga P Chalasani; William C Goggins; John A Powelson; Oscar W Cummings
Journal:  Transplantation       Date:  2007-01-15       Impact factor: 4.939

3.  Glycogenic hepatopathy and non-alcoholic fatty liver disease in type 1 diabetes patients.

Authors:  Mamoru Saikusa; Shuichi Yatsuga; Tatsuyuki Tonan; Yasutoshi Koga
Journal:  Pediatr Int       Date:  2013-12       Impact factor: 1.524

4.  Glycogenic hepatopathy: a rare cause of elevated serum transaminases in diabetes mellitus.

Authors:  M van den Brand; L D Elving; J P H Drenth; J H J M van Krieken
Journal:  Neth J Med       Date:  2009-12       Impact factor: 1.422

5.  The bright liver of glycogenic hepatopathy.

Authors:  Seth Sweetser; Robert E Kraichely
Journal:  Hepatology       Date:  2010-02       Impact factor: 17.425

6.   Glycogenic hepatopathy associated with type 1 diabetes mellitus as a cause of recurrent liver damage.

Authors:  Sara Messeri; Luca Messerini; Francesco Vizzutti; Giacomo Laffi; Fabio Marra
Journal:  Ann Hepatol       Date:  2012 Jul-Aug       Impact factor: 2.400

7.  Asenapine pharmacokinetics in hepatic and renal impairment.

Authors:  Pierre Peeters; Howard Bockbrader; Edwin Spaans; Peter Dogterom; Kenneth Lasseter; Thomas Marbury; Gordon L Gibson; Rik de Greef
Journal:  Clin Pharmacokinet       Date:  2011-07       Impact factor: 6.447

8.  Hepatomegaly and abnormal liver tests due to glycogenosis in adults with diabetes.

Authors:  R Chatila; A B West
Journal:  Medicine (Baltimore)       Date:  1996-11       Impact factor: 1.889

9.  A case of glycogenic hepatopathy developed in a patient with new-onset fulminant type 1 diabetes: the role of image modalities in diagnosing hepatic glycogen deposition including gradient-dual-echo MRI.

Authors:  Fumi Murata; Ichiro Horie; Takao Ando; Eriko Isomoto; Hideyuki Hayashi; Satoru Akazawa; Ikuko Ueki; Kan Nakamura; Masakazu Kobayashi; Hironaga Kuwahara; Norio Abiru; Eiji Kawasaki; Hironori Yamasaki; Atsushi Kawakami
Journal:  Endocr J       Date:  2012-05-12       Impact factor: 2.349

10.  Safety of paliperidone extended-release in patients with schizophrenia or schizoaffective disorder and hepatic disease.

Authors:  Joan Amatniek; Carla M Canuso; Stephen I Deutsch; David C Henderson; Lian Mao; Chris Mikesell; Stephen Rodriguez; John Sheehan; Larry Alphs
Journal:  Clin Schizophr Relat Psychoses       Date:  2014-04
View more
  1 in total

Review 1.  Glycogenic hepatopathy: A narrative review.

Authors:  Jagannath M Sherigar; Joline De Castro; Yong Mei Yin; Debra Guss; Smruti R Mohanty
Journal:  World J Hepatol       Date:  2018-02-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.